



Universiteit  
Leiden  
The Netherlands

## **Osteosarcoma : searching for new treatment options**

Baranski Madrigal, Z.

### **Citation**

Baranski Madrigal, Z. (2016, May 26). *Osteosarcoma : searching for new treatment options*. Retrieved from <https://hdl.handle.net/1887/39707>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/39707>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/39707> holds various files of this Leiden University dissertation.

**Author:** Baranski Madrigal, Z.

**Title:** Osteosarcoma : searching for new treatment options

**Issue Date:** 2016-05-26

## LIST OF PUBLICATIONS

**Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma**

*Zuzanna Baranski, Tijmen H. Booij, Anne-Marie Cleton-Jansen, Leo Price, Bob van de Water, Judith V. M. G. Bovée, Pancras C.W. Hogendoorn, Erik H.J. Danen. J Pathol* **236**:348-359, 2015

**Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin**

*Zuzanna Baranski, Yvonne de Jong, Trayana Ilkova, Elisabeth F.P. Peterse, Anne-Marie Cleton-Jansen, Bob van de Water, Pancras C.W. Hogendoorn, Judith V. M. G. Bovée, Erik H.J. Danen. Oncotarget* **6**:36113-36125, 2015

**MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation**

*Zuzanna Baranski, Tijmen H. Booij, Marieke L. Kuijjer, Yvonne de Jong, Anne-Marie Cleton-Jansen, Leo S. Price, Bob van de Water, Judith V. M. G. Bovée, Pancras C.W. Hogendoorn, Erik H.J. Danen. Genes and Cancer, in press* 2015

**SYK Is a Candidate Kinase Target for the Treatment of Advanced Prostate Cancer**

*Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM, Verhoef EI, Baranski Z, Xiong J, van de Water B, van der Pluijm G, Snaar-Jagalska BE, Danen EH. Cancer Research* **75**:230-240, 2015

**Dasatinib Src inhibitor selectively triggers apoptosis and loss of invasive potential in human osteosarcoma cells**

*Zuzanna Baranski, Tijmen H. Booij, Anne-Marie Cleton-Jansen, Leo Price, Bob van de Water, Judith V. M. G. Bovée, Pancras C.W. Hogendoorn, Erik H.J. Danen. Manuscript in preparation*

## **CURRICULUM VITAE**

Zuzanna Baranski Madrigal was born on the 21<sup>st</sup> of March of 1981 in San Jose, Costa Rica. She studied Pharmacy at the University of Costa Rica from 2000 to 2006. After obtaining her degree, she worked as a pharmacist in Costa Rica from 2006 to 2008. After this period, she travelled to The Netherlands to obtain her Master degree in Biopharmaceutical Sciences at Leiden University. She obtained her degree in 2011.

In 2011 she started as a PhD student at the department of Toxicology at LACDR Institute in Leiden University, under the supervision of Dr. Erik Danen. The project was part of the Translational Drug Discovery and Development grant: Identification and validation of novel kinase drug targets for sarcoma growth & therapy resistance.

She started a postdoctoral fellowship with Dr. Erik Danen the 1<sup>st</sup> of February, 2016.